KalVista Pharmaceuticals Inc (STU:4XC1)
€ 9.2 -0.5 (-5.15%) Market Cap: 456.06 Mil Enterprise Value: 296.04 Mil PE Ratio: 0 PB Ratio: 2.56 GF Score: 34/100

Kalvista Pharmaceuticals Inc KVD900 Phase 2 Topline Results Conference Call Transcript

Feb 09, 2021 / 01:30PM GMT
Release Date Price: €28.4 (+125.40%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to KalVista Pharmaceuticals Conference Call. (Operator Instructions) And as a reminder, this conference call is being recorded.

I would now like to turn the call over to your host, Ms. Leah Monteiro. Ma'am, you may begin.

Leah Monteiro
KalVista Pharmaceuticals, Inc. - Senior Director of Corporate Communications & IR

Thank you. Joining me on today's call are Andy Crockett, KalVista's Chief Executive Officer; Ben Palleiko, our Chief Business Officer and Chief Financial Officer; and Chris Yea, our Chief Development Officer.

Commentary made on this call may include forward-looking statements. These forward-looking statements are based on management's current views and expectations as of today and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to update forward-looking statements or outlook. Actual results may differ materially. Please refer to the risk factors in our most recent 10-Q filed with the SEC.

I will now

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot